Hosein Kouros-Mehr
Senior Vice President, R&D Myriad Genetics
Seminars
Tuesday 21st July 2026
Clinical Validation of Myriad Genetics’ Ultra-Sensitive Pan-Cancer WGS-Based Precise MRD Assay
12:30 pm
- Join this deep-dive session to understand how ultra-sensitive, tumor-informed MRD testing is being applied across clinical and development settings
- Walk away with a clear view of where ultra-sensitive MRD testing delivers value today
- Understand how to apply it across your own programs
